207 related articles for article (PubMed ID: 34602806)
1. Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir.
Wang T; Kadow JF; Meanwell NA
Med Chem Res; 2021; 30(11):1955-1980. PubMed ID: 34602806
[TBL] [Abstract][Full Text] [Related]
2. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
Meanwell NA; Krystal MR; Nowicka-Sans B; Langley DR; Conlon DA; Eastgate MD; Grasela DM; Timmins P; Wang T; Kadow JF
J Med Chem; 2018 Jan; 61(1):62-80. PubMed ID: 29271653
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
Wang T; Ueda Y; Zhang Z; Yin Z; Matiskella J; Pearce BC; Yang Z; Zheng M; Parker DD; Yamanaka GA; Gong YF; Ho HT; Colonno RJ; Langley DR; Lin PF; Meanwell NA; Kadow JF
J Med Chem; 2018 Jul; 61(14):6308-6327. PubMed ID: 29920093
[TBL] [Abstract][Full Text] [Related]
5. Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection.
Chahine EB
Am J Health Syst Pharm; 2021 Feb; 78(5):376-388. PubMed ID: 33547469
[TBL] [Abstract][Full Text] [Related]
6. Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir.
Magee M; Slater J; Mannino F; Ackerman P; Llamoso C; Moore K
J Clin Pharmacol; 2021 Jul; 61(7):939-953. PubMed ID: 33368327
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants.
Wire MB; Magee M; Ackerman P; Llamoso C; Moore K
HIV Res Clin Pract; 2021 Dec; 23(1):1-8. PubMed ID: 35285786
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients.
Saladini F; Giannini A; Giammarino F; Maggiolo F; Vichi F; Corbelli GM; Galli A; Bigoloni A; Poli A; Santoro MM; Zazzi M; Castagna A
J Antimicrob Chemother; 2020 Sep; 75(9):2547-2553. PubMed ID: 32464638
[TBL] [Abstract][Full Text] [Related]
9. Small Molecule HIV-1 Attachment Inhibitors: Discovery, Mode of Action and Structural Basis of Inhibition.
Lai YT
Viruses; 2021 May; 13(5):. PubMed ID: 34066522
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
Thompson M; Lalezari JP; Kaplan R; Pinedo Y; Pena OAS; Cahn P; Stock DA; Joshi SR; Hanna GJ; Lataillade M;
Antivir Ther; 2017; 22(3):215-223. PubMed ID: 27922453
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay.
Gartland M; Zhou N; Stewart E; Pierce A; Clark A; Ackerman P; Llamoso C; Lataillade M; Krystal M
J Antimicrob Chemother; 2021 Feb; 76(3):648-652. PubMed ID: 33241285
[TBL] [Abstract][Full Text] [Related]
12. Fostemsavir: First Approval.
Markham A
Drugs; 2020 Sep; 80(14):1485-1490. PubMed ID: 32852743
[TBL] [Abstract][Full Text] [Related]
13. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
[TBL] [Abstract][Full Text] [Related]
14. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
Kozal M; Aberg J; Pialoux G; Cahn P; Thompson M; Molina JM; Grinsztejn B; Diaz R; Castagna A; Kumar P; Latiff G; DeJesus E; Gummel M; Gartland M; Pierce A; Ackerman P; Llamoso C; Lataillade M;
N Engl J Med; 2020 Mar; 382(13):1232-1243. PubMed ID: 32212519
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Clinical Envelopes With Lack of Sensitivity to the HIV-1 Inhibitors Temsavir and Ibalizumab.
Gartland M; Stewart E; Zhou N; Li Z; Rose R; Beloor J; Clark A; Tenorio AR; Krystal M
Antiviral Res; 2024 Jul; ():105957. PubMed ID: 38971430
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir.
Saladini F; Giannini A; Giammarino F; Boccuto A; Dragoni F; Vicenti I; Zazzi M
J Antimicrob Chemother; 2021 Nov; 76(12):3310-3312. PubMed ID: 34402509
[No Abstract] [Full Text] [Related]
17. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043).
Kadow JF; Ueda Y; Meanwell NA; Connolly TP; Wang T; Chen CP; Yeung KS; Zhu J; Bender JA; Yang Z; Parker D; Lin PF; Colonno RJ; Mathew M; Morgan D; Zheng M; Chien C; Grasela D
J Med Chem; 2012 Mar; 55(5):2048-56. PubMed ID: 22356441
[TBL] [Abstract][Full Text] [Related]
18. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
Zhang Y; Chapman JH; Ulcay A; Sutton RE
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
[TBL] [Abstract][Full Text] [Related]
19. Composition and Orientation of the Core Region of Novel HIV-1 Entry Inhibitors Influences Metabolic Stability.
Karadsheh R; Meuser ME; Cocklin S
Molecules; 2020 Mar; 25(6):. PubMed ID: 32245167
[TBL] [Abstract][Full Text] [Related]
20. Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.
Alessandri-Gradt E; Charpentier C; Leoz M; Mourez T; Descamps D; Plantier JC
J Antimicrob Chemother; 2018 Oct; 73(10):2716-2720. PubMed ID: 30032194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
